MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462210 | Name: LEI 101 hydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LEI 101 hydrochloride is potent and selective CB2 partial agonist.

Chemical Structure

LEI 101 hydrochloride
LEI 101 hydrochloride
CAS#2250025-91-1

Theoretical Analysis

MedKoo Cat#: 462210

Name: LEI 101 hydrochloride

CAS#: 2250025-91-1

Chemical Formula: C23H26ClFN4O4S

Exact Mass: 508.1347

Molecular Weight: 508.99

Elemental Analysis: C, 54.27; H, 5.15; Cl, 6.96; F, 3.73; N, 11.01; O, 12.57; S, 6.30

Price and Availability

Size Price Availability Quantity
10mg USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
LEI 101 hydrochloride; LEI 101 HCl
IUPAC/Chemical Name
3-Cyclopropyl-1-[[4-[6-[(1,1-dioxido-4-thiomorpholinyl)methyl]-5-fluoro-2-pyridinyl]phenyl]methyl]-2,4-imidazolidinedione hydrochloride
InChi Key
APLLNJWPLUIBCG-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H25FN4O4S.ClH/c24-19-7-8-20(25-21(19)14-26-9-11-33(31,32)12-10-26)17-3-1-16(2-4-17)13-27-15-22(29)28(23(27)30)18-5-6-18;/h1-4,7-8,18H,5-6,9-15H2;1H
SMILES Code
O=C1N(C2CC2)C(CN1CC3=CC=C(C4=NC(CN5CCS(CC5)(=O)=O)=C(F)C=C4)C=C3)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG.
In vitro activity:
LEI-101 behaved as a partial agonist at CB2 receptors using β-arrestin and GTPγS assays and was ~100-fold selective in CB2 /CB1 receptor-binding assays. Reference: Br J Pharmacol. 2016 Feb;173(3):446-58. https://pubmed.ncbi.nlm.nih.gov/21923175/
In vivo activity:
Systematic modification of physicochemical properties, such as lipophilicity and basicity, was used to optimize the pharmacokinetic profile and hERG affinity of this novel class of cannabinoid CB2 receptor agonists. This led to the identification of 44 (LEI 101) as a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist (hCB2 pEC(50) = 8.0; hERG pK(i) < 4; F(po) = 100%), which was active in a rat spinal nerve ligation model of neuropathic pain. Reference: J Med Chem. 2011 Oct 27;54(20):7350-62. https://pubmed.ncbi.nlm.nih.gov/21923175/
Solvent mg/mL mM
Solubility
DMSO 50.9 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 508.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15. PMID: 26398481; PMCID: PMC4728411. 2. van der Stelt M, Cals J, Broeders-Josten S, Cottney J, van der Doelen AA, Hermkens M, de Kimpe V, King A, Klomp J, Oosterom J, Pols-de Rooij I, de Roos J, van Tilborg M, Boyce S, Baker J. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J Med Chem. 2011 Oct 27;54(20):7350-62. doi: 10.1021/jm200916p. Epub 2011 Sep 29. PMID: 21923175.
In vitro protocol:
1. Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15. PMID: 26398481; PMCID: PMC4728411. 2. van der Stelt M, Cals J, Broeders-Josten S, Cottney J, van der Doelen AA, Hermkens M, de Kimpe V, King A, Klomp J, Oosterom J, Pols-de Rooij I, de Roos J, van Tilborg M, Boyce S, Baker J. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J Med Chem. 2011 Oct 27;54(20):7350-62. doi: 10.1021/jm200916p. Epub 2011 Sep 29. PMID: 21923175.
In vivo protocol:
1. Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15. PMID: 26398481; PMCID: PMC4728411. 2. van der Stelt M, Cals J, Broeders-Josten S, Cottney J, van der Doelen AA, Hermkens M, de Kimpe V, King A, Klomp J, Oosterom J, Pols-de Rooij I, de Roos J, van Tilborg M, Boyce S, Baker J. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J Med Chem. 2011 Oct 27;54(20):7350-62. doi: 10.1021/jm200916p. Epub 2011 Sep 29. PMID: 21923175.
1: van der Stelt M, Cals J, Broeders-Josten S, et al. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J Med Chem. 2011;54(20):7350-7362. doi:10.1021/jm200916p 2: Mukhopadhyay P, Baggelaar M, Erdelyi K, et al. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol. 2016;173(3):446-458. doi:10.1111/bph.13338